Diabetic Nephropathies, Hypertension
Conditions
Keywords
Adalat XL, Diltiazem, Tiazac XC, Proteinuria
Brief summary
The study consists of a 12 week run-in period when all subjects are stabilized on a single dose of Avalide (300 mg/12.5 mg or 300mg/25mg dose) per day. After this 12 week run-in ends, subjects will be randomly assigned to start the addition of either Adalat XL or Tiazac XC for 18 weeks of treatment. Subjects will have a 1 in 2 chance of receiving the study drug Adalat XL and a 1 in 2 chance of receiving the drug Tiazac XC. An end of treatment visit will be done 18 weeks after start of study drug. The expected duration of the study is 30 weeks. The purpose of this study is to compare the change in proteinuria, through a urine test, while taking study drug until high blood pressure (BP) is reduced to near normal levels in study subjects with diabetic nephropathy and hypertension.
Interventions
DRUGAdalat XL
Patients will receive Avalide (Irbesartan/ hydrochlorothiazide; 300 mg/12.5 mg per day or 300 mg/25.0 mg per day) during the 12 week screening period and during the 18 week treatment period. At baseline, patients will be provided with Adalat XL at a starting dose of 20 or 30 mg. Adalat XL will be titrated during the 18 week treatment period in order to optimize blood pressure. Adalat XL will be supplied in 20 mg, 30 mg, 60 mg, and 90 mg.
DRUGTiazac XC
Patients will receive Avalide (Irbesartan/ hydrochlorothiazide; 300 mg/12.5 mg per day or 300 mg/25.0 mg per day) during the 12 week screening period and during the 18 week treatment period. At baseline, patients will be provided with Tiazac XC at a starting dose of 180 mg. Tiazac XC will be titrated during the 18 week treatment period in order to optimize blood pressure. Tiazac XC will be supplied in 180 mg, 240 mg, 300 mg and 360 mg.
Sponsors
Bayer
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* \>/= 18 and \< 80 years old. * Diagnosed with hypertension. * Diagnosed with diabetes mellitus type 2 for at least 6 mths prior to entry and on stable medication for diabetes for at 1 mth prior to screening. * Treated on ARB, ACE inhibitor with or without hydrochlorothiazide and suitable to receive combination therapy with Avalide at 300mg/12.5mg per day or 300mg/25mg per day. * Diagnosed with diabetic nephropathy and have proteinuria between 0.8g/day and 5.0g/day at screening and then between 0.8g/day and 3.0g/day at randomization. * Medically appropriate to receive Adalat XL or Tiazac XC.
Exclusion criteria
* History of alcohol or substance abuse. * Significant CV disorder such as ischemic heart disease, arrhythmias within the last 6 mths, or any history of severe congestive heart failure. * Myocarditis or pericarditis within last 30 day of screening. * ECG showing evidence of major arrhythmia or conduction disturbances requiring treatment with anti-arrhythmic medication. * Females with child-bearing potential or males with a partner of child-bearing potential unless willing to use effective contraception during the study and 3 mths after the end of study. * Females who are pregnant, lactating or planning pregnancy during the study and for 3 mths after the study end. * Known hypersensitivity to Adalat XL or Tiazac XC or other calcium channel blockers of the dihydropyridine class. * Resting heart rate \<50 or \>110 bpm. * Presence of secondary or malignant hypertension. * DBP \>/= 180 and/or SBP \>/= 110 mmHg.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Proteinuria | Baseline/Randomization to Week 18 |
Secondary
| Measure | Time frame |
|---|---|
| Number and doses of anti-hypertensives used in the 2 treatment arms | Baseline/Randomization to Week 18 |
| Levels of urinary albumin and protein content and estimated glomerular filtration rate (GFR) in the 2 treatment groups | Baseline/Randomization to Week 18 |
| Early BP reduction from randomization achieved with the starting dose in the 2 treatment arms | Baseline/Randomization to Week 1 |
| Percentage of subjects reaching a BP target of 130/80 mmHg at Week 18 | Baseline/Randomization to Week 18 |
| All Adverse Events especially, edema | Screening to end of study |
| Change in index of glycemia (HbA1c) | Screening to Week 18 |
| Adverse Events leading to early withdrawal | Screening to end of study |
Outcome results
None listed